Show simple item record

dc.contributor.authorMadariaga, A
dc.contributor.authorRustin, GJS
dc.contributor.authorBuckanovich, RJ
dc.contributor.authorTrent, JC
dc.contributor.authorOza, AM
dc.date.accessioned2019-06-27T11:59:12Z
dc.date.issued2019-01
dc.identifier.citationAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2019, 39 pp. e152 - e166
dc.identifier.issn1548-8748
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3280
dc.identifier.eissn1548-8756
dc.identifier.doi10.1200/edbk_238755
dc.description.abstractEpithelial ovarian cancer has a very high rate of relapse after primary therapy; historically approximately 70% of patients with a complete clinical response to surgery and adjuvant chemotherapy will relapse and die of the disease. Although this number has slowly improved, cure rates remain less than 50%. As such, maintenance therapy with the aim of preventing or delaying disease relapse and the goal of improving overall survival has been the subject of intense study. Numerous earlier studies with agents ranging from radioactive phosphorus to extended frontline therapy or to monthly taxol administration demonstrated encouraging improvements in progression-free survival (PFS) only to find, disappointingly, no benefit in overall survival. In addition, the PFS advantage of maintenance therapy was associated with disconcerting side effects such that maintenance therapy was not adapted as standard of care. Studies with bevacizumab and PARP inhibitors have demonstrated a PFS advantage with a manageable side-effect profile. However, an overall survival advantage remains unclear, and the use of these approaches thus remains controversial. Furthermore, in recurrent disease, the length of chemotherapy and benefits of extended chemotherapy is unclear. Thus, additional trials assessing maintenance strategies in ovarian and other gynecologic malignancies are needed.
dc.formatPrint-Electronic
dc.format.extente152 - e166
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectGenital Neoplasms, Female
dc.subjectRecurrence
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectTreatment Outcome
dc.subjectChemotherapy, Adjuvant
dc.subjectDrug Resistance, Neoplasm
dc.subjectResearch Design
dc.subjectFemale
dc.subjectClinical Trials as Topic
dc.subjectMolecular Targeted Therapy
dc.subjectConsolidation Chemotherapy
dc.subjectMaintenance Chemotherapy
dc.subjectBiomarkers, Tumor
dc.titleWanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.
dc.typeJournal Article
rioxxterms.versionofrecord10.1200/edbk_238755
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume39
pubs.embargo.termsNot known
dc.contributor.icrauthorRustin, Gordon


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0